C4 Therapeutics
CCCC · NASDAQ
$3.16+$0.27 (+9.34%)TodayMarket closed ·
Prev close $2.89
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 24.3% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.2309 | -$0.18 | +22.0% |
| Q1 FY26 | -$0.3794 | -$0.20 | +47.3% |
| Q4 FY25 | -$0.3098 | -$0.18 | +41.9% |
| Q3 FY25 | -$0.4143 | -$0.44 | −6.2% |
| Q2 FY25 | -$0.3917 | -$0.37 | +5.5% |
| Q1 FY25 | -$0.459 | -$0.37 | +19.4% |
| Q4 FY24 | -$0.4873 | -$0.49 | −0.6% |
| Q3 FY24 | -$0.3876 | -$0.35 | +9.7% |
Earnings calls
- Special Call - C4 Therapeutics, Inc.
- Barclays 28th Annual Global Healthcare Conference
- Special Call - C4 Therapeutics, Inc.
- 43rd Annual J.P. Morgan Healthcare Conference 2025
- Special Call - C4 Therapeutics, Inc.
- Special Call - C4 Therapeutics, Inc.
- UBS Virtual Targeted Protein Degradation (TPD) Day
- J.P. Morgan 42nd Annual Healthcare Conference 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.